EASE services are tailored to fit the needs of patients

1-844-900-EASE (3273) 9:00 am to 8:00 pm ET, Monday to Friday

EASE provides solutions to the potential hurdles your office and patients may encounter, with the following programs to help access CABOMETYX tablets. EASE Representatives can provide information and answer questions relating to coverage, specialty pharmacy shipments, and financial assistance options/eligibility.*

Quick Start

Your patients who experience insurance coverage decision delays don't have to wait to initiate therapy

  • A supply of CABOMETYX for new patients, with refills as needed (for up to 60 days)

How to Enroll Patients in Quick Start

  1. Complete the EASE Enrollment Form
    NOTE: Ensure patient's name and date of birth are filled out on the top of page 2
  2. Complete Quick Start prescription (Section 5)
  3. Sign Sections 5 and 6
    EASE will verify payer delay and dispense Quick Start supply until coverage determination is made for up to 60 days
If you are an in-office dispenser, please check box for "Specialty Pharmacy Referral Not Needed" (Section 4).

Dose Exchange Program

Support your patients who require dose reductions to their therapy with CABOMETYX

  • Patients receive a free one-time supply of CABOMETYX tablets in the new dose strength

How to Enroll Patients in the Dose Exchange Program

  1. Complete the Dose Exchange Form
  2. Sign and submit the form to EASE
  3. EASE ships the new dose strength tablets to your patient and helps the patient return their unused tablets

Alternate Funding Assistance

Help address access hurdles for patients who cannot afford therapy

  • PAP free product is available to patients who qualify

How to Enroll Patients in Alternate Funding Assistance

  1. Complete the EASE Enrollment Form
  2. Have patients complete and sign Patient Authorization Form
    EASE can provide assistance with alternative funding options and determine PAP eligibility
If you are an in-office dispenser, please check box for "Specialty Pharmacy Referral Not Needed" (Section 4).

Ease Co-Pay Program

(for patients with commercial insurance)

$10 Maximum Monthly Co-Pay

  • Eligible commercial patients pay no more than $10 per month, for a maximum benefit of $25,000 per year

How to Enroll Patients in the EASE Co-Pay Program

  1. Complete the EASE Enrollment Form
  2. EASE will enroll eligible commercial patients

Free Trial Program

Get your eligible new patients started with a free trial of CABOMETYX

  • To learn more, contact your local Exelixis® Oncology Account Manager
  • Limited quantities are available
For a complete list of EASE forms, please visit the Resources section

*This description of the Exelixis® Access Services program is for informational purposes only. Exelixis® makes no representation or guarantee concerning reimbursement or coverage for any service or item. Information provided through the Exelixis® Access Services program does not constitute medical or legal advice and is not intended to be a substitute for a consultation with a licensed healthcare provider, legal counsel, or applicable third-party payer(s). Exelixis® reserves the right to modify the program at any time without notice.
Limited to the following ICD-10 diagnoses: C64, C64.1, C64.2, and C64.9. Other restrictions may apply.

Distributors of CABOMETYX

What happens next: Advancing your prescription to the specialty pharmacy

  1. Complete the EASE Enrollment Form
  2. EASE will enroll eligible commercial patients
Specialty Pharmacies
Accredo 1-800-803-2523 www.accredo.com
Advanced Care Scripts (ACS) 1-866-681-7131 www.acs-rx.com
Biologics, Inc. 1-800-850-4306 www.biologicsinc.com
CVS Caremark 1-800-237-2767 www.cvsspecialty.com
Diplomat 1-877-977-9118 www.diplomatpharmacy.com
Walgreens 1-888-380-6188 www.walgreenshealth.com
Specialty Distributors
Cardinal Health Specialty Distribution 1-855-740-1871 specialtyonline.cardinalhealth.com
McKesson Specialty Health 1-800-482-6700 www.mckessonspecialtyhealth.com
Oncology Supply 1-800-633-7555 www.oncologysupply.com
Institutions/Hospitals
McKesson Plasma and Biologics 1-877-625-2566 connect.mckesson.com
ASD Healthcare 1-800-746-6273 www.asdhealthcare.com
Next: Resources »

Indication

CABOMETYX® (cabozantinib) is a kinase inhibitor indicated for the treatment of patients with advanced renal cell carcinoma (RCC).

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

  • Hemorrhage: Severe and fatal hemorrhages have occurred with CABOMETYX. In RCC trials, the incidence of Grade ≥3 hemorrhagic events was 3% in CABOMETYX patients. Do not administer CABOMETYX to patients that have or are at risk for severe hemorrhage.
  • Gastrointestinal (GI) Perforations and Fistulas: In RCC trials, GI perforations were reported in 1% of CABOMETYX patients. Fatal perforations occurred in patients treated with CABOMETYX. In RCC studies, fistulas were reported in 1% of CABOMETYX patients. Monitor patients for symptoms of perforations and fistulas, including abscess and sepsis. Discontinue CABOMETYX in patients who experience a GI perforation or a fistula that cannot be appropriately managed.
  • Thrombotic Events: Thrombotic events increased with CABOMETYX. In RCC trials, venous thromboembolism occurred in 9% (including 5% pulmonary embolism) and arterial thromboembolism occurred in 1% of CABOMETYX patients. Fatal thrombotic events occurred in the cabozantinib clinical program. Discontinue CABOMETYX in patients who develop an acute myocardial infarction or any other arterial thromboembolic complication.
  • Hypertension and Hypertensive Crisis: Treatment-emergent hypertension, including hypertensive crisis, increased with CABOMETYX. In RCC trials, hypertension was reported in 44% (18% Grade ≥3) of CABOMETYX patients. Monitor blood pressure prior to initiation and regularly during CABOMETYX treatment. Withhold CABOMETYX for hypertension that is not adequately controlled with medical management; when controlled, resume CABOMETYX at a reduced dose. Discontinue CABOMETYX if there is evidence of hypertensive crisis or for severe hypertension that cannot be controlled with antihypertensive therapy or medical management.
  • Diarrhea: In RCC trials, diarrhea occurred in 74% of CABOMETYX patients. Grade 3 diarrhea occurred in 11% of CABOMETYX patients. Withhold CABOMETYX in patients who develop intolerable Grade 2 diarrhea or Grade 3-4 diarrhea that cannot be managed with standard antidiarrheal treatments until improvement to Grade 1; resume CABOMETYX at a reduced dose.
  • Palmar-Plantar Erythrodysesthesia (PPE): In RCC trials, PPE occurred in 42% of CABOMETYX patients. Grade 3 PPE occurred in 8% of CABOMETYX patients. Withhold CABOMETYX in patients who develop intolerable Grade 2 PPE or Grade 3 PPE until improvement to Grade 1; resume CABOMETYX at a reduced dose.
  • Reversible Posterior Leukoencephalopathy Syndrome (RPLS): RPLS, a syndrome of subcortical vasogenic edema diagnosed by characteristic finding on MRI, occurred in the cabozantinib clinical program. Evaluate for RPLS in patients presenting with seizures, headache, visual disturbances, confusion, or altered mental function. Discontinue CABOMETYX in patients who develop RPLS.
  • Embryo-fetal Toxicity: CABOMETYX can cause fetal harm. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during CABOMETYX treatment and for 4 months after the last dose.

ADVERSE REACTIONS

The most commonly reported (≥25%) adverse reactions were: diarrhea, fatigue, nausea, decreased appetite, hypertension, PPE, weight decreased, vomiting, dysgeusia, and stomatitis.

DRUG INTERACTIONS

  • Strong CYP3A4 Inhibitors: If concomitant use with strong CYP3A4 inhibitors cannot be avoided, reduce the CABOMETYX dosage.
  • Strong CYP3A4 Inducers: If concomitant use with strong CYP3A4 inducers cannot be avoided, increase the CABOMETYX dosage.

USE IN SPECIFIC POPULATIONS

  • Lactation: Advise women not to breastfeed while taking CABOMETYX and for 4 months after the final dose.
  • Hepatic Impairment: In patients with mild to moderate hepatic impairment, reduce the CABOMETYX dosage. CABOMETYX is not recommended for use in patients with severe hepatic impairment.

Please see accompanying full Prescribing Information by clicking here.

IMDC=International Metastatic Renal Cell Carcinoma Database Consortium; TKI=tyrosine kinase inhibitor.

Reference: 1. CABOMETYX® (cabozantinib) Prescribing Information. Exelixis Inc., 2017.

+

Indication and Important Safety Information

Indication

CABOMETYX® (cabozantinib) is a kinase inhibitor indicated for the treatment of patients with advanced renal cell carcinoma (RCC).

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

  • Hemorrhage: Severe and fatal hemorrhages have occurred with CABOMETYX. In RCC trials, the incidence of Grade ≥3 hemorrhagic events was 3% in CABOMETYX patients. Do not administer CABOMETYX to patients that have or are at risk for severe hemorrhage.